Company Overview

PRIME exits® and American HealthCare Capital are pleased to introduce a clinical trial service business for sale that provides comprehensive healthcare, clinical research, and technology services to global pharmaceutical and biotech organizations. With a network of more than 1,600 registered clinical sites worldwide, including hospitals, private clinics, and research centers, the company has established strong partnerships with major sponsors such as Pfizer, GSK, and other industry leaders.

Clients benefit from a dedicated study manager who ensures each project is set up for success and managed with precision. Core services include:

• Network Sites – Business development, Protocol feasibility process, Study start-up and sponsor visits and communications for all network sites. The company also operates an offshore modern facility designed to support its overall operations.

• Technology Access – A secure online portal offering an all-in-one platform for managing research activities and studies efficiently.

• Patient Recruitment – Tailored recruitment strategies based on indication, demographics, and study timelines.

• Budgeting Assistance – Expert support for study budgeting, with additional guidance for organizations new to clinical research.

• Patient Management – Robust tracking and documentation tools to oversee enrollment, amendments, and progress across studies.

• Learning Resources – Free access to professional courses, live instruction, and downloadable templates to support site success.

New Tech Platform

In addition to its established Clinical Research operations, the company is launching KerloSense, a next-generation technology platform that substantially enhances enterprise value. Designed to address inefficiencies in clinical research, KerloSense enables seamless global collaboration by connecting sponsors, clinical research facilities, and site management organizations (SMOs). With its scalable, all-in-one model, the platform introduces high-margin, recurring revenue opportunities while expanding market reach. Positioned as a disruptive force within the clinical research industry, KerloSense strengthens the company’s long-term growth trajectory and unlocks significant value creation for investors.

Key Features include:

• SITE SEARCH AND STUDY SEARCH- tailored search and filtering

• BILLING & INVOICING-secure, seamless invoicing and payment management.

• PATIENT MANAGEMENT-easy scheduling and invoicing for patient visits

• LEARNIING MANAGEMENT SYSTEM-streamlined onboarding and training for research teams

• SMO NETWORK MANAGEMENT- connect with SMO’s and recruitment companies to optimize success.

Financial Performance

The company has demonstrated consistent year-over-year growth and is positioned for its strongest performance yet. In 2023, revenue reached $2.8 million with an EBITDA of $614,500. In 2024, revenue grew to just over $3 million with EBITDA of $685,000. Projections for 2025 exceed $4 million in revenue and $875,000 in EBITDA, supported by multiple new studies and expanded revenue streams.

Exit Strategy

With a strong track record, proven service model, and scalable infrastructure, the company is strategically positioned to drive continued expansion and deliver sustained returns. The owner is pursuing an earn-out purchase structure, with mutually defined terms anchored by an initial valuation at closing and a follow-up valuation one-year post-acquisition. Supported by a healthy pipeline and significant market demand, the business offers compelling growth potential and value creation for investors. The founders remain flexible and are prepared to stay actively engaged for up to one year if desired, ensuring continuity, or to provide a structured transition with a defined exit strategy.

Asking Price

The sellers have allocated the asking price between the two components of the business: the established Clinical Research operations, valued at $7 million, and the newly developed Tech Platform, valued at $3 million, resulting in a total asking price of $10 million, plus an earnout component.